Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Delta(9)-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS). The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects could be effective as well. To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.11 out of 13 included patients completed the study. The 11-Point-Box-Test showed a significant decrease of pain under Nabilone (p < 0.05), while spasticity, motor function and activities of daily living did not change. 5 patients reported side effects: one moderate transient weakness of the lower limbs (Nabilone phase, drop out), three mild drowsiness (two Nabilone, one placebo) and one mild dysphagia (placebo). One patient was excluded from the study due to an acute relapse of multiple sclerosis (Nabilone phase, drop out). Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nabilone decreased pain by a median of 2 points compared with 0 points with placebo (p<0.05).”
From Nabilone for the Management of Pain (2016) · cites this paper as [22]
In the citing paper
“One case each of multiple sclerosis relapse and weakness in the lower limbs were also documented, but only the weakness was attributed to nabilone.22”
From Nabilone for the Management of Pain (2016) · cites this paper as [22]
In the citing paper
“These processes have a number of characteristics in common with chronic neuropathic pain or fibromyalgia, chronic conditions for which nabilone has been tested with encouraging results [15–17].”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [16]
In the citing paper
“Nabilone (Cesamet®) decreased measures of spasticity-related pain (11-Point Box Test) in patients experiencing chronic upper motor neuron syndrome (UMNS) associated with a number of pain syndromes.160”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [160]
Citations
Cites
Verapamil: A Review of its Pharmacological Properties and Therapeutic Use1
Singh, B. N., Ellrodt, G., & Peter, C. T. (1978) · Drugs · doi:10.2165/00003495-197815030-00001 · Cited by 832
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
Campbell, F. A., Tramèr, M. R., Carroll, D., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.13 · Cited by 423
Endocannabinoids control spasticity in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0399fje · Cited by 378
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
Anti-spasticity agents for multiple sclerosis
Shakespeare, D., Boggild, M., & Young, C. A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001332 · Cited by 271
Treatments for spasticity and pain in multiple sclerosis: a systematic review
Beard, S., Hunn, A., & Wight, J. (2003) · Health Technology Assessment · doi:10.3310/hta7400 · Cited by 266
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
Killestein, J., Hoogervorst, E. L. J., Reif, M., Kalkers, N. F., van Loenen, A. C., Staats, P. G. M., Gorter, R. W., Uitdehaag, B. M. J., & Polman, C. H. (2002) · Neurology · doi:10.1212/wnl.58.9.1404 · Cited by 209
Research works printed but not linked: 1
- Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534–551 · DOI · Paper page
Cited by
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
“…(Arevalo-Martin et al., 2003; Pryce et al., 2003; Zajicek et al., 2003; Ni et al., 2004; Maresz et al., 2005; Rog et al., 2005; Freeman et al., 2006; Wissel et al., 2006; Centonze et al., 2007; Collin et al., 2007; Palazuelos et al., 2008; Zhang et al., 2009) Cell-based therapies Neural stem cells…”
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
Hill, K. P. (2015) · JAMA · doi:10.1001/jama.2015.6199 · Cited by 508
Pain associated with multiple sclerosis: Systematic review and proposed classification
O’Connor, A. B., Schwid, S. R., Herrmann, D. N., Markman, J. D., & Dworkin, R. H. (2008) · Pain · doi:10.1016/j.pain.2007.08.024 · Cited by 498
“Finally, the synthetic cannabinoid nabilone was studied in a crossover trial involving 13 MS patients; it was found to reduce spasticity-related pain and was reasonably well tolerated, but it did not improve spasticity or motor function [105].”
BackgroundStockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Metadata
- Authors
- Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D.
- Affiliations
- Universität Innsbruck (AT)
- Kantonsspital Münsterlingen (CH)
- Corresponding author
- Wissel, Jörg
- Venue
- Journal of Neurology
- Published
- 2006-09-20
- Volume
- 253
- Issue
- 10
- Pages
- 1337-1341
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2167045148
- Cited by
- 171
- References
- 31
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 11 · 2021: 7 · 2020: 12 · 2019: 4 · 2018: 18 · 2017: 10 · 2016: 9 · 2015: 10 · 2014: 9 · 2013: 2 · 2012: 9
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Rehabilitation › Cerebral Palsy and Movement Disorders
- Keywords
- nabilone, spasticity-related pain, upper motor neuron syndrome, multiple sclerosis, synthetic cannabinoids, low-dose therapy, pain management, drug safety, adverse effects
- MeSH terms
- Activities of Daily Living, Adolescent, Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Muscle Spasticity, Pain, Pain Measurement, Recurrence, Dronabinol, Motor Neuron Disease, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. https://app.cochat.ai/papers/10.1007/s00415-006-0218-8
- The paper
- Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006). Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. Journal of Neurology. https://doi.org/10.1007/s00415-006-0218-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.